Treatment and Management of Interstitial Lung Disease (ILD)

Paul Noble, MD, and Daniel Culver, DO, explain the definition of interstitial lung disease (ILD), as well as certain conditions that fall within that distinction.

Kristin Highland, MD, discusses the common risk factors associated with ILD.

Daniel Culver, DO, and Paul Noble, MD, talk about incidence and prevalence typically seen with patients with ILD.

Daniel Culver, DO, and Paul Noble, MD, highlight the types of physicians who manage patients with different forms of ILD, from diagnosis to treatment, as well as the process of referrals.

Ryan Haumschild, PharmD, MS, MBA, and Kristin Highland, MD, explain the clinical and economic burdens associated with ILD treatment.

Drs Noble and Highland explain the typical treatment goals physicians aim for when looking at ILD therapy options.

The panel provides an overview of the treatment landscape for idiopathic pulmonary fibrosis (IPF) and progressing fibrosing ILD (PF-ILD).

Dr Kristin Highland continues the treatment landscape discussion, focusing on systemic sclerosis ILD (SSc-ILD) and clinical trial data that studied therapy options for IPF, PF-ILD, and SSc-ILD.

Daniel Culver, DO, concludes the clinical trial discussion by elaborating on Dr Highland’s assessments of the data that support the use of nintedanib, pirfenidone, and tocilizumab when treating IPF, PF-ILD, and SSc-ILD.

Dr Paul Noble comments on the role lung transplants play in ILD treatment.

Kristin Highland, MD, and Ryan Haumschild, PharmD, MS, MBA, compare management tools to self-regulation for the best ILD treatment outcome, as well as patient access to nintedanib, pirfenidone, and tocilizumab through special pharmacies.

Daniel Culver, DO, details how COVID-19 has impacted the treatment of ILD.

The panel participants relay unmet needs they have found when treating ILD, and discuss promising therapy developments that could improve the treatment landscape.

The panel concludes by offering key takeaways for viewers and listeners on ILD therapy.

Dr Paul Noble, MD discusses updates and changes in ATS-directed guidelines for the treatment of ILD.

Dr Noble, MD provides and overview of the treatment landscape surrounding ILD, specifically examining IPF, PPF, and SSc-ILD antifibrotic therapy.

ILD treatment options approved by the FDA are explored by Dr Noble, MD.

Dr Noble discusses recent ATS guidelines regarding the use of pirfenidone in ILD.

Nintedanib recommendations for use from the recent ATS guidelines and treatment implementation are considered by Paul Noble, MD.

Paul Noble, MD, provides his closing thoughts on payer perspectives surrounding ILD, as well as considerations for the trajectory of ILD treatment landscape.